GlassScriptPhysician profile
Justin Matthew Spaulding
NPI 1013259167
$68,864.92
in general payments reported to CMS, 2019-2025
25 companies · $64K in 2025
The $64K reported for 2025 was more than what 98% of Glaucoma Specialist providers received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $350 · 2020: $188 · 2021: $234 · 2022: $2,817 · 2023: $769 · 2024: $661 · 2025: $64K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $60K · Travel and Lodging: $2,855 · Food and Beverage: $2,422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $60,000.00 |
| Travel and Lodging | $2,855.33 |
| Food and Beverage | $2,421.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $63,509.05 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Nova Eye, INC. | $2,471.10 | 2021-2023 | |
| Alcon Vision LLC | $1,062.82 | 2019-2025 | Hydrus Microstent, Centurion, Clareon Panoptix Pro |
| Sun Pharmaceutical Industries INC. | $228.35 | 2019-2025 | Cequa |
| Glaukos Corporation | $180.81 | 2022-2025 | Idosetr |
| Novartis Pharmaceuticals Corporation | $164.13 | 2022-2023 | |
| Abbvie INC. | $145.18 | 2024-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $122.88 | 2019 | |
| Biotissue Holdings INC. | $114.73 | 2019-2020 | |
| Allergan, INC. | $111.78 | 2020-2022 | |
| Rxsight INC | $110.07 | 2025 | Rxsight Light Delivery Device (Ldd), Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Harrow Eye, LLC | $105.65 | 2024-2025 | Iheezo |
| New World Medical,INC. | $104.07 | 2022-2025 | Ahmed Glaucoma Valve, Streamline, Clearpath |
| Dompe US, INC. | $76.79 | 2024-2025 | Oxervate |
| Aerie Pharmaceuticals, INC. | $65.17 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $46.44 | 2023-2024 | Syfovre |
| Ellexiscience | $45.07 | 2019 | |
| Oyster Point Pharma, INC. | $42.52 | 2022-2024 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $37.71 | 2024-2025 | Xdemvy |
| Ivantis, INC | $30.75 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $30.13 | 2025 | Eylea Hd, Eylea |
| Amgen INC. | $25.34 | 2025 | Tepezza |
| Alimera Sciences, INC. | $17.98 | 2024 | Iluvien, Yutiq |
| Horizon Therapeutics Plc | $16.40 | 2023 | Tepezza |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Spaulding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.